Opinion|Videos|September 22, 2023
DESTINY-CRC02 Trial: Trastuzumab Deruxtecan for the Management of mCRC
Daniel Ahn, DO, and Tanios Bekaii-Saab, MD, detail the findings of the DESTINY-CRC02 trial, which examined the efficacy of trastuzumab deruxtecan at different dosing levels in breast cancer and gastric cancer patients.
Advertisement
Episodes in this series
Advertisement
Related to this article
More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
2
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
3
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
4
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
5